Tags : DR

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

Tuba Khan August 26, 2019

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary […]readmore

Pharma

Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Trial

Vartika Singh February 11, 2019

Shots: The P-III PANORAMA Trial involves assessing of Eylea (aflibercept) vs sham injection in 402 patients with moderately severe to severe NPDR in without DME for 16 wks. or 8 […]readmore

Tags : DR

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : DR

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company